| Similar Articles |
|---|
 |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.   |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Scientific American
January 17, 2007
Charles Q. Choi |
A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Repairing The Engines Of Life Can research into stem cells and other advanced techniques heal ailing hearts and brains? U.S. labs are hamstrung by the federal government. |
Scientific American
July 2008
Sally Lehrman |
Dolly's Creator Moves Away from Cloning and Embryonic Stem Cells Like many stem cell pioneers, Ian Wilmut, the creator of Dolly the sheep, has jumped to an alternative approach. Is this the beginning of the end for embryonic cloning? |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Young Again Niche cells can reverse the aging of stem cells. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
BusinessWeek
February 12, 2007
Bruce Einhorn |
Stem-Cell Refugees Americans are flocking to China for therapy. |
HHMI Bulletin
Aug 2011
Richard Saltus |
T-Cell Booster Kits A bioengineer remodels cell surfaces to prod the immune system. |
Popular Mechanics
January 28, 2010
Cassie Rodenberg |
Next-Gen Transplant Techniques Can Stop Organ Rejection About 77 organ transplants are performed each day in the U.S., and more than 101,000 people are on a wait list for body parts such as hearts, skin and veins, according to the Mayo Clinic. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
BusinessWeek
July 26, 2004
Arlene Weintraub |
The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
Popular Mechanics
November 27, 2007
Alex Hutchinson |
Stem Cells 2.0: Beyond the Hype, Engineers Look to Build Fast Engineers play the important role of making lab bench discoveries reproducible and efficient for use in industry. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
Chemistry World
February 4, 2011
Harriet Brewerton |
Transplant tracking Magnetic nanoparticles could be used to track neural stem cells after a transplant in order to monitor how the cells heal spinal injuries, say UK scientists. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
BusinessWeek
January 23, 2006
Arlene Weintraub |
A "Body Blow" To Stem Cell Research Funding for stem cell research in the U.S. wasn't so hot even before the Korean scandal broke. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
BusinessWeek
December 6, 2004
Catherine Arnst |
Cord Blood To The Rescue A study in the Nov. 25 issue of The New England Journal of Medicine confirms that stem cells in blood extracted from the umbilical cords of newborns can help leukemia patients |
Reactive Reports
Issue 64
David Bradley |
Stem to Sperm New research shows that stem cells from human bone marrow can be converted into early-stage sperm. The discovery could lead to novel fertility treatments in the long-term. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
Salon.com
December 29, 2000
Arthur Allen |
Will Thompson, Bush clash over human embryo research? The HHS nominee supports it, but right-to-lifers want it stopped.... |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
Scientific American
March 2007
Alison Snyder |
Sight for Sore Eyes Having generated a cell source and overcome the safety concerns associated with transplanting stem cells, researchers still face possibly their biggest challenge: showing that the transplanted photoreceptors wire up to other neurons that eventually connect to the optic nerves. |
Chemistry World
July 22, 2010
Mike Brown |
Microspheres help restore eyesight Polymer microspheres could deliver stem cells to the eyes of patients whose sight has been destroyed by age-related macular degeneration to repair the damage and enable them to see clearly again, say researchers in the UK. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
Reason
October 2001
Ronald Bailey |
Blastocyst Brouhaha Which human cells count as people? |
Salon.com
August 21, 2000
Lori B. Andrews |
Embryos under the knife The latest reproductive technology is just the next step on our sprint toward human cloning. |
Reason
July 2005
Ronald Bailey |
Censored Science Speaking out on stem cells: The Washington Post noted that even President Bush's handpicked NIH director, Elias Zerhouni, may not be on board with administration's stem cell policy. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission. |
